A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

Active, not recruitingOBSERVATIONAL
Enrollment

427

Participants

Timeline

Start Date

March 30, 2020

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Hemophilia A
Interventions
DRUG

ELOCTA

Extended half-life factor VIII product

Trial Locations (53)

Unknown

University Hospital Brno, Brno

University Hospital Ostrava, Ostrava

Dept. of Pediatric Haematology and Oncology, University Hospital Motol, Prague

Lastehaigla, Tallinn (Tallinn Children´s Hospital), Tallinn

The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla, Tallinn

Helsinki University Central Hospital, New Children Hospital, Helsinki

Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic, Turku

Charité-Universitätsmedizin Berlin Campus Virchow Klinikum, Berlin

Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn

Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum, Frankfurt

Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin, Frankfurt

Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg

Medizinische Hochschule Hannover, Hanover

Werlhof-Institut für Hämostaseologie GmbH, Hanover

SRH-Klinikum Heidelberg, Heidelberg

HZRM Hämöphilie Zentrum Rhein Main, Mörfelden-Walldorf

Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München, München

Ippokrateio Hospital Thessaloniki (adult department), Thessaloniki

Ippokrateio Hospital Thessaloniki (pediatric department), Thessaloniki

University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.), Bari

AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini, Cesena

Giannina Gaslini Institute, Genova

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan

University Hospital of Parma, AOUP, Haemophilia Center, Parma

Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure, Rome

Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita, Torino

University Medical Center Groningen/UMCG, Groningen

The Royal Hospital, Muscat

Dr Suliman Al Habib Hospital Riyadh, Riyadh

King Faisal Specialised Hospital, KFSH Riyadh, Children, Riyadh

King Faisal Specialist Hospital KFSH, Adults, Riyadh

Riyadh Military Hospital (P.S.M.C), Riyadh

University Medical Centre Ljubljana Division of Paediatrics, Ljubljana

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Vall d'Hebron, Barcelona

Sant Johan De Deu, Barcelona

Hospital Universitario Cruces, Cruces

Hospital Universitario Donostia, Donostia / San Sebastian

Hospital Universitario Carlos Haya, Málaga

Hospital Virgen de la Arrixaca, Murcia

Complejo Hospitalario de Navarra, Navarro

Hospital Universitario Central de Asturias (HUCA), Oviedo

Hospital Universitario Son Espases, Palma de Mallorca

Hospital Universitario Virgen del Rocío, Seville

Hospital Alvaro Cunqueiro, Vigo

Hematologimottagning Sahlgrenska, Gothenburg

Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö, Malmo

Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital, Bern

Service et Laboratoire central d'hématologie, Adults, Lausanne

Zentrum für Labormedizin, Sankt Gallen

Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie, Zurich

East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital, Canterbury

Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine, London

Sponsors
All Listed Sponsors
lead

Swedish Orphan Biovitrum

INDUSTRY